Chugai and Taisho to Co-Develop and Market Antiresorptive Bisphosphonate R484.Tokyo, Japan, Sept 13, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社 Co., Ltd. have agreed to co-develop and market antiresorptive bisphosphonate R484, (generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : ibandronic acid Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva®, Bondronat® and Bonviva®, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. ) for treatment of osteoporosis in post-menopausal women. Under the agreement, Chugai will receive an upfront fee and milestone payments from Taisho. R484 is currently in phase II clinical trials in Japan and is expected to be the next generation osteoporosis treatment drug. It is marketed under the brand name Bonviva in the U.S. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion